The main goal of the Career Development Program is to prepare new investigators for independent careers in lung cancer research. It is expected that Career Development Awardees will spend between two and four years in a productive scientific environment, after which time they will establish independent programs in research related to lung cancer, either at institutions affiliated with the University of Colorado Lung Cancer SPORE or another institution. The Career Development committee annually reviews the progress of each awardee by receiving reports and by discussions with the awardee and the awardee's mentor. The Career Development committee also solicits applications for new awardees. This is done by campus-wide mailings and on some occasions by national letters and journal advertisements. Applicants complete a written application that is reviewed by the committee and the committee also interviews the applicants. The committee makes recommendations to the SPORE Executive Committee which makes final selection and determines the amount of the award in consultation with the applicant and mentor. Institutional funds are used to increase the award amounts above those provided by the grant. For the renewal period we are requesting $50,000 annually. This will be matched with up to $50,000 of institutional funds to provide an average of $50,000 to each of two awardees per year. We believe the program has been successful. Since its inception in 1993, the SPORE has provided support to 20 awardees. Nine of these continue to work on lung cancer. In addition, three other awardees continue scientific investigation in industry and two are academic laboratory investigators. One awardee is in private practice and one retired to care for her family. Three of the awardees are from underrepresented minority groups and 7 are female. No major changes are anticipated in the program with the exception of an increase in the award amounts.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Colorado Denver
United States
Zip Code
Oweida, Ayman; Lennon, Shelby; Calame, Dylan et al. (2017) Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma. Oncoimmunology 6:e1356153
Blakely, Collin M; Watkins, Thomas B K; Wu, Wei et al. (2017) Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet 49:1693-1704
Tan, Aik-Choon; Vyse, Simon; Huang, Paul H (2017) Exploiting receptor tyrosine kinase co-activation for cancer therapy. Drug Discov Today 22:72-84
Ziemke, Michael; Patil, Tejas; Nolan, Kyle et al. (2017) Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer. Lung Cancer 109:28-35
Gao, Boning; Huang, Chunxian; Kernstine, Kemp et al. (2017) Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions. Oncotarget 8:11114-11126
Gautschi, Oliver; Milia, Julie; Filleron, Thomas et al. (2017) Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. J Clin Oncol 35:1403-1410
Li, Howard Y; McSharry, Maria; Bullock, Bonnie et al. (2017) The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade. Cancer Immunol Res 5:767-777
McCoach, C E; Blumenthal, G M; Zhang, L et al. (2017) Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy. Ann Oncol 28:2707-2714
Vaishnavi, Aria; Schubert, Laura; Rix, Uwe et al. (2017) EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases. Cancer Res 77:3551-3563
Bruno, Tullia C; Ebner, Peggy J; Moore, Brandon L et al. (2017) Antigen-Presenting Intratumoral B Cells Affect CD4+ TIL Phenotypes in Non-Small Cell Lung Cancer Patients. Cancer Immunol Res 5:898-907

Showing the most recent 10 out of 397 publications